Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
The FDA is set to make approval decisions on five new treatments before year-end 2026, spanning conditions from lupus to obesity to kidney transplantation. The pipeline includes obinutuzumab for SLE, CagriSema for weight management, imsidolimab for pustular psoriasis, imlifidase for kidney transplant desensitization, and lorundrostat for resistant hypertension. Each drug showed statistically significant results in Phase 3 trials.
The FDA has a busy December ahead, with five PDUFA decisions expected across rheumatology, endocrinology, dermatology, nephrology, and cardiology. These potential approvals could bring new treatment options to patients with conditions that are often difficult to manage with existing therapies.
Here's a quick rundown of what's on the docket:
Why it matters: These approvals could meaningfully expand treatment options for patients with limited alternatives — from autoimmune diseases to obesity to end-stage kidney disease — and signal a strong close to 2026 for the FDA drug pipeline.